Refractory Peripheral T-Cell Lymphoma, Relapsed T-Cell Lymphoma
Conditions
Keywords
FOT12-CN-301, PTCL (peripheral T-cell lymphoma), pralatrexate, vitamin B12, folic acid
Brief summary
This is a single arm, open-label, multi-center study designed to demonstrate the efficacy and safety of pralatrexate when administered concurrently with vitamin B12 and folic acid supplementation to patients with relapsed or refractory peripheral T-cell lymphoma(PTCL).
Detailed description
The primary objective of this study is to confirm the objective response rate (ORR) among Chinese subjects with relapsed or refractory PTCL treated with pralatrexate together with concurrent vitamin B12 and folic acid supplementation Primary endpoint is objective Response Rate by International Working Group Criteria This study includes 3 phases: Screening, Treatment (pralatrexate) and Follow-up phases. Screening Phase: The screening phase will be up to 28 days duration (depending on availability of lab results). Treatment (pralatrexate) Phase: The start of study treatment (pralatrexate) is defined as the initiation of pralatrexate. Patients will attend the clinic weekly for 6 weeks of a 7-week cycle to receive pralatrexate, and will be examined by the treating physician. One cycle of pralatrexate therapy is 7 weeks in duration and consists of 6 weekly doses of pralatrexate administered via intravenous (IV) push over 3-5 minutes, followed by 1 week of rest. Evaluation of response must be performed within 7 days prior to the projected first dose of cycle 2-4 and then within 7 days prior to the projected first dose of every even-numbered subsequent cycle (ie, prior to cycles 6, 8, etc.). Although radiological response assessments have been scheduled every 14 weeks, unscheduled radiological response assessments will be performed earlier if clinical progression is suspected. Treatment with pralatrexate will continue until 24 months of administration, or until documented disease progression; unacceptable adverse event(s) indicating intolerance of the lowest study dose allowed (20 mg/m2/week); omission of 3 sequential doses of pralatrexate due to a treatment-related AE; 3-week lapse between pralatrexate doses; development of an AE, intercurrent illness, condition, or procedural complication that may interfere with the subject's participation; investigator's decision to withdraw the subject; subject withdraws consent; pregnancy of the subject; noncompliance with trial treatment or procedure requirements; or administrative reasons. Follow-up phase: All patients who received at least 1 dose of pralatrexate are to attend the Safety Follow-up Visit \[30 (± 5) days after the last dose of pralatrexate\] and the protocol defined procedures and evaluations will be performed. After the Safety Follow-up Visit, Routine Follow-up Visits will be based on standard clinical care. All patients who received at least 1 dose of pralatrexate are to attend Routine Follow-up Visits, which will occur every 3 months (± 2 weeks) for determination of progression of disease, subsequent treatment initiation for T-cell lymphoma and survival after the Safety Follow-up Visit for a total duration of 24 months after the last dose of pralatrexate. The protocol-defined procedures/evaluations should be performed at each Routine Follow-up Visit.
Interventions
DRUGpralatrexate
Pralatrexate will be administered at a dose of 30 mg/m2/week for 6 weeks followed by 1 week of rest in a 7-week cycle. Pralatrexate administration occurs once a week during week 1 through week 6 of each cycle.
DIETARY_SUPPLEMENTVitamin B12 and folic acid
The eligible subjects will receive vitamin supplementation at screening phase, at least 10 days prior to pralatrexate administration on cycle 1, dose 1. Vitamin supplementation will consist of vitamin B12 1 mg intramuscular (IM) q 8-10 weeks and folic acid 1.2mg by mouth (PO) once a day (QD). Once pralatrexate is permanently discontinued, vitamin supplementation should continue at least 1 month after the last pralatrexate dose, or longer at the discretion of the investigator.
Sponsors
Mundipharma (China) Pharmaceutical Co. Ltd
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Subject has histologically/cytologically confirmed PTCL, using the World Health Organization (WHO) disease classification: 1. PTCL not otherwise specified (NOS) 2. Angioimmunoblastic T-cell lymphoma 3. Anaplastic large cell lymphoma, ALK+ 4. Anaplastic large cell lymphoma, ALK- 5. Extranodal NK/T-cell lymphoma - nasal type 6. Enteropathy-associated T cell lymphoma 7. Hepatosplenic T-cell lymphoma 8. Subcutaneous panniculitis-like T-cell lymphoma 9. Adult T-cell lymphoma/leukemia (human T-cell leukemia virus \[HTLV\] 1+) 10. Aggressive NK-cell leukemia 11. Transformed mycosis fungoides 2. Subject has to have documented progressive disease (PD) after at least 1 prior systemic treatment. 3. Subject may not have received an experimental drug or biologic as their only prior therapy. Subject must have clear PD after the last treatment received. Subject should have at least 1 biopsy from initial diagnosis or in the relapsed setting to confirm the diagnosis of PTCL. Subject must have recovered from the toxic effects of prior therapy. 4. Subjects with an enlarged lymph node or extranodal mass lesion clearly measurable in two perpendicular directions and greater than 1.5 cm maximum diameter on computed tomography performed within 14 days prior to study enrollment. 5. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2. 6. At least 18 years of age. 7. Expected life expectancy ≥ 3 months. 8. Adequate hematological, hepatic, and renal function as defined by: * Absolute neutrophil count (ANC) ≥ 1000/uL (or 1\*109/L), platelet count ≥ 100,000/uL (or 100\*109/L) (at both screening and within 3 days prior to dosing on cycle 1, day 1) * Total bilirubin ≤ 1.5 mg/dL, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 X upper limit of normal (ULN) (AST/ALT \< 5 X ULN if documented hepatic involvement with lymphoma) * Creatinine ≤ 1.5 mg/dL (or 132.6 µmol/L) or a calculated creatinine clearance ≥ 50 mL/min 9. Women of childbearing potential must have agreed to practice a medically acceptable contraceptive regimen from study treatment initiation until at least 30 days after the last administration of pralatrexate and must have a negative serum pregnancy test within 14 days prior to the first day of study treatment. Subjects who are postmenopausal for at least 1 year (\> 12 months since last menses) or are surgically sterilized did not require this test. 10. Men who are not surgically sterile must agree to practice a medically acceptable contraceptive regimen from study treatment initiation until at least 90 days after the last administration of pralatrexate. 11. Subject gives written informed consent (IC).
Exclusion criteria
1. Subject has: 1. Precursor T-cell lymphoma or leukemia 2. T-cell prolymphocytic leukemia (T-PLL) 3. T-cell large granular lymphocytic leukemia 4. Mycosis fungoides, other than transformed mycosis fungoides 5. Sézary syndrome 6. Primary cutaneous CD30+ T-cell disorders: Lymphoid papulosis and primary cutaneous anaplastic large cell lymphoma 2. Active concurrent malignancy (except non-melanoma skin cancer or carcinoma in situ of the cervix). If there is a history of prior malignancy, the patient must be disease-free for ≥ 5 years. 3. Congestive heart failure Class III/IV according to the New York Heart Association's Heart Failure guidelines. 4. Human immunodeficiency virus (HIV)-positive diagnosis. 5. Has, or history of, brain metastases or central nervous system (CNS) disease. 6. Active uncontrolled infection, underlying medical condition including unstable cardiac disease, or other serious illness that would impair the ability of the subject to receive protocol treatment. 7. Has major surgery within 2 weeks of study entry. 8. Receipt of any conventional chemotherapy or radiation therapy (RT) within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to study treatment or planned use during the course of the study. 9. Receipt of corticosteroids within 7 days of study treatment, unless subject has been taking a continuous systemic dose of no more than 10 mg/day or equivalent dose of prednisone, or a local or inhaled or intranasal administration at fixed doses for at least 1 month prior to study treatment and tumor shrinkage was not observed. 10. Use of any investigational drugs, biologics, or devices within 4 weeks prior to study treatment or planned use during the course of the study. 11. Receipt of anti-tumor antibody therapy within 100 days prior to study treatment. 12. History of allogeneic hematopoietic stem cell transplantation. Or subjects with a history of autologous hematopoietic stem cell transplantation within 100 days prior to study treatment. 13. Previous exposure to pralatrexate. 14. Subject is pregnant or breast-feeding
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate(ORR) by International Working Group Criteria | 2 years | ORR defined as the percentage of subjects with CR, CRu or PR as Best Overall Response.Evaluation of response must be performed within 7 days prior to the projected first dose of cycle 2-4 and then within 7 days prior to the projected first dose of every even-numbered subsequent cycle (i.e. prior to cycles 6, 8, etc). Unscheduled radiological response assessments will be performed earlier if clinical progression is suspected.The primary analysis will be conducted once all subjects have completed cycle 5 treatment or discontinued before. Study treatment may continue per investigator judgment for a maximum of 24 months. Response will be assessed on the basis of clinical, radiological, and pathological criteria. Response will be assessed by independent central review and by the treating investigator. Central review assessors will be blinded to the response assessments by the treating investigator. The primary analysis will be based on response assessed by central review. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-Free Survival (PFS) | 2 years | PFS was measured from treatment day 1 until event or censoring. An event was defined as the earliest of the following: death from any cause or disease progression. Subjects undergoing transplant or any other subsequent therapy prior to documentation of PD was censored at that time. Progression of disease deems as 1. 50% increase from nadir in the SPD of any previously identified abnormal node for PRs or nonresponders, 2.Appearance of any new lesion during or at the end of therapy as per IWC criteria. |
| Overall Survival (OS) | 4 years | OS was measured from treatment day 1 until death or censoring. |
| Duration of Responses | 4 years | Duration of response was measured from first day of documented response to disease progression or death, whatever comes first. |
| Percentage of Participants With Treatment Emergent Adverse Events | 4 years | treatment emergent AE was scheduled to be collected during all subject visits, the data evaluated as clinical significant will be summarized and presented. |
| Area Under the Curve [AUC] for R-pralatrexate | Cycle 1 day1，Cycle 1 week 6(Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection) | The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population. |
| Area Under the Curve [AUC] for S-pralatrexate | Cycle 1 day 1, Cycle 1 week 6（Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection） | The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population. |
| Steady State Volume of Distribution [Vdss] for R-pralatrexate | Cycle 1 day 1, Cycle 1 week6(Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection) | The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population. |
| Steady State Volume of Distribution [Vdss] for S-pralatrexate | Cycle 1 day 1, Cycle 1 week 6（Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection） | The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population. |
| Time to Response (TTR) | 2 years | Time to response was measured from first day of treatment to the first date of documented response. |
| Steady State Clearance [CLss] for S-pralatrexate | Cycle 1 day 1, Cycle 1 week 6（Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection） | The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population. |
| Maximum Observed Plasma Concentration [Cmax] for R-pralatrexate | Cycle 1 day 1, Cycle 1 week 6（Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection） | The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population. |
| Maximum Observed Plasma Concentration [Cmax] for S-pralatrexate | Cycle 1 day 1, Cycle 1 week 6（Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection） | The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population. |
| Time of Cmax Observation [Tmax] for R-pralatrexate | Cycle 1 day 1, Cycle 1 week 6（Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection） | The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population. |
| Time of Cmax Observation [Tmax] for S-pralatrexate | Cycle 1 day 1, Cycle 1 week 6（Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection） | The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population. |
| Terminal Phase Half-life [t1/2Z] for R-pralatrexate | Cycle 1 day 1, Cycle 1 week 6（Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection） | The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population. |
| Terminal Phase Half-life [t1/2Z] for S-pralatrexate | Cycle 1 day 1, Cycle 1 week 6（Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection） | The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population. |
| Steady State Clearance [CLss] for R-pralatrexate | Cycle 1 day 1, Cycle 1 week 6（Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection） | The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population. |
Countries
China
Participant flow
Pre-assignment details
In the protocol, 85 patients are planned to enroll. However, 71 patients are treated in the real situation.
Participants by arm
| Arm | Count |
|---|---|
| PTCL Subtype Vitamin B12 and folic acid will be taken concurrently with pralatrexate
pralatrexate: Pralatrexate will be administered at a dose of 30 mg/m2/week for 6 weeks followed by 1 week of rest in a 7-week cycle. Pralatrexate administration occurs once a week during week 1 through week 6 of each cycle.
Vitamin B12 and folic acid: The eligible subjects will receive vitamin supplementation at screening phase, at least 10 days prior to pralatrexate administration on cycle 1, dose 1. Vitamin supplementation will consist of vitamin B12 1 mg intramuscular (IM) q 8-10 weeks and folic acid 1.2mg by mouth (PO) once a day (QD). Once pralatrexate is permanently discontinued, vitamin supplementation should continue at least 1 month after the last pralatrexate dose, or longer at the discretion of the investigator. | 71 |
| Total | 71 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | 3-week lapse between pralatrexate doses | 1 |
| Overall Study | Adverse Event | 11 |
| Overall Study | Conditions interfere with participation | 2 |
| Overall Study | Other | 6 |
| Overall Study | Patients in treatment less than 24 month | 8 |
| Overall Study | Physician Decision | 2 |
| Overall Study | Progression of Disease | 36 |
| Overall Study | Withdrawal by Subject | 5 |
Baseline characteristics
| Characteristic | PTCL Subtype |
|---|---|
| Age, Customized Age(years) | 54.5 years STANDARD_DEVIATION 12.52 |
| Baseline Characteristics Subtype of PTCL from central review Adult T-cell lymphoma/leukemia (human T-cell leuke | 1 Participants |
| Baseline Characteristics Subtype of PTCL from central review Anaplastic large cell lymphoma, ALK- | 6 Participants |
| Baseline Characteristics Subtype of PTCL from central review Anaplastic large cell lymphoma, ALK+ | 2 Participants |
| Baseline Characteristics Subtype of PTCL from central review Angioimmunoblastic T-cell lymphoma | 20 Participants |
| Baseline Characteristics Subtype of PTCL from central review Enteropathy-associated T cell lymphoma | 1 Participants |
| Baseline Characteristics Subtype of PTCL from central review Extranodal NK/T-cell lymphoma - nasal type | 5 Participants |
| Baseline Characteristics Subtype of PTCL from central review other | 1 Participants |
| Baseline Characteristics Subtype of PTCL from central review PTCL not otherwise specified (NOS) | 34 Participants |
| Baseline Characteristics Subtype of PTCL from central review Subcutaneous panniculitis-like T-cell lymphoma | 1 Participants |
| Baseline Characteristics Subtype of PTCL from investigator Adult T-cell lymphoma/leukemia (human T-cell leuke | 1 Participants |
| Baseline Characteristics Subtype of PTCL from investigator Anaplastic large cell lymphoma, ALK- | 7 Participants |
| Baseline Characteristics Subtype of PTCL from investigator Anaplastic large cell lymphoma, ALK+ | 2 Participants |
| Baseline Characteristics Subtype of PTCL from investigator Angioimmunoblastic T-cell lymphoma | 19 Participants |
| Baseline Characteristics Subtype of PTCL from investigator Enteropathy-associated T cell lymphoma | 1 Participants |
| Baseline Characteristics Subtype of PTCL from investigator Extranodal NK/T-cell lymphoma - nasal type | 5 Participants |
| Baseline Characteristics Subtype of PTCL from investigator other | 0 Participants |
| Baseline Characteristics Subtype of PTCL from investigator PTCL not otherwise specified (NOS) | 34 Participants |
| Baseline Characteristics Subtype of PTCL from investigator Subcutaneous panniculitis-like T-cell lymphoma | 2 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 71 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 0 Participants |
| Region of Enrollment China | 71 Participants |
| Sex: Female, Male Female | 24 Participants |
| Sex: Female, Male Male | 47 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 29 / 71 |
| other Total, other adverse events | 70 / 71 |
| serious Total, serious adverse events | 35 / 71 |
Outcome results
Primary
Objective Response Rate(ORR) by International Working Group Criteria
ORR defined as the percentage of subjects with CR, CRu or PR as Best Overall Response.Evaluation of response must be performed within 7 days prior to the projected first dose of cycle 2-4 and then within 7 days prior to the projected first dose of every even-numbered subsequent cycle (i.e. prior to cycles 6, 8, etc). Unscheduled radiological response assessments will be performed earlier if clinical progression is suspected.The primary analysis will be conducted once all subjects have completed cycle 5 treatment or discontinued before. Study treatment may continue per investigator judgment for a maximum of 24 months. Response will be assessed on the basis of clinical, radiological, and pathological criteria. Response will be assessed by independent central review and by the treating investigator. Central review assessors will be blinded to the response assessments by the treating investigator. The primary analysis will be based on response assessed by central review.
Time frame: 2 years
Population: The primary analysis was based on the independent review data using the safety population, safety population is 71 for this study
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Pralatrexate | Objective Response Rate(ORR) by International Working Group Criteria | 37 Participants |
Secondary
Area Under the Curve [AUC] for R-pralatrexate
The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.
Time frame: Cycle 1 day1，Cycle 1 week 6(Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection)
Population: Based on PK population
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Pralatrexate | Area Under the Curve [AUC] for R-pralatrexate | Pralatrexate-R in Cycle 1 week 6（20mg/m2） | 2350.7402 h*ng/ml | Geometric Coefficient of Variation 28.22 |
| Pralatrexate | Area Under the Curve [AUC] for R-pralatrexate | Pralatrexate-R in Cycle 1 week 6（30mg/m2） | 3979.1069 h*ng/ml | Geometric Coefficient of Variation 152.16 |
| Pralatrexate | Area Under the Curve [AUC] for R-pralatrexate | Pralatrexate-R in Cycle 1 day 1（30mg/m2） | 3586.2925 h*ng/ml | Geometric Coefficient of Variation 43.7 |
Secondary
Area Under the Curve [AUC] for S-pralatrexate
The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.
Time frame: Cycle 1 day 1, Cycle 1 week 6（Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection）
Population: PK population
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Pralatrexate | Area Under the Curve [AUC] for S-pralatrexate | Pralatrexate-S in Cycle 1 week 6（20mg/m2） | 1364.7686 h*ng/ml | Geometric Coefficient of Variation 22.65 |
| Pralatrexate | Area Under the Curve [AUC] for S-pralatrexate | Pralatrexate-S in Cycle 1 week 6（30mg/m2） | 2182.5078 h*ng/ml | Geometric Coefficient of Variation 264.05 |
| Pralatrexate | Area Under the Curve [AUC] for S-pralatrexate | Pralatrexate-S in Cycle 1 day 1（30mg/m2） | 1674.8773 h*ng/ml | Geometric Coefficient of Variation 38.32 |
Secondary
Duration of Responses
Duration of response was measured from first day of documented response to disease progression or death, whatever comes first.
Time frame: 4 years
Population: The secondary analyses was performed using the safety population and repeated using the per-protocol population.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Pralatrexate | Duration of Responses | 8.67 months |
Secondary
Maximum Observed Plasma Concentration [Cmax] for R-pralatrexate
The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.
Time frame: Cycle 1 day 1, Cycle 1 week 6（Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection）
Population: PK population
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Pralatrexate | Maximum Observed Plasma Concentration [Cmax] for R-pralatrexate | Pralatrexate-R in Cycle 1 day 1（30mg/m2） | 4649.6811 ng/mL | Geometric Coefficient of Variation 83.74 |
| Pralatrexate | Maximum Observed Plasma Concentration [Cmax] for R-pralatrexate | Pralatrexate-R in Cycle 1 week 6（20mg/m2） | 2488.1502 ng/mL | Geometric Coefficient of Variation 17.78 |
| Pralatrexate | Maximum Observed Plasma Concentration [Cmax] for R-pralatrexate | Pralatrexate-R in Cycle 1 week 6（30mg/m2） | 5064.6667 ng/mL | Geometric Coefficient of Variation 421.48 |
Secondary
Maximum Observed Plasma Concentration [Cmax] for S-pralatrexate
The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.
Time frame: Cycle 1 day 1, Cycle 1 week 6（Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection）
Population: PK population
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Pralatrexate | Maximum Observed Plasma Concentration [Cmax] for S-pralatrexate | Pralatrexate-S in Cycle 1 week 6（30mg/m2） | 3439.9695 ng/mL | Geometric Coefficient of Variation 697.55 |
| Pralatrexate | Maximum Observed Plasma Concentration [Cmax] for S-pralatrexate | Pralatrexate-S in Cycle 1 day 1（30mg/m2） | 3727.8582 ng/mL | Geometric Coefficient of Variation 118.25 |
| Pralatrexate | Maximum Observed Plasma Concentration [Cmax] for S-pralatrexate | Pralatrexate-S in Cycle 1 week 6（20mg/m2） | 2325.5105 ng/mL | Geometric Coefficient of Variation 24.22 |
Secondary
Overall Survival (OS)
OS was measured from treatment day 1 until death or censoring.
Time frame: 4 years
Population: The secondary analyses was performed using the safety population and repeated using the per-protocol population.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Pralatrexate | Overall Survival (OS) | 18.00 months |
Secondary
Percentage of Participants With Treatment Emergent Adverse Events
treatment emergent AE was scheduled to be collected during all subject visits, the data evaluated as clinical significant will be summarized and presented.
Time frame: 4 years
Population: safety population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Pralatrexate | Percentage of Participants With Treatment Emergent Adverse Events | 98.6 percentage of participants |
Secondary
Progression-Free Survival (PFS)
PFS was measured from treatment day 1 until event or censoring. An event was defined as the earliest of the following: death from any cause or disease progression. Subjects undergoing transplant or any other subsequent therapy prior to documentation of PD was censored at that time. Progression of disease deems as 1. 50% increase from nadir in the SPD of any previously identified abnormal node for PRs or nonresponders, 2.Appearance of any new lesion during or at the end of therapy as per IWC criteria.
Time frame: 2 years
Population: The secondary analyses was performed using the safety population and repeated using the per-protocol population.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Pralatrexate | Progression-Free Survival (PFS) | 4.76 months |
Secondary
Steady State Clearance [CLss] for R-pralatrexate
The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.
Time frame: Cycle 1 day 1, Cycle 1 week 6（Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection）
Population: PK population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Pralatrexate | Steady State Clearance [CLss] for R-pralatrexate | Pralatrexate-R Cycle 1 Day 1 (30 mg/m2) | 17.1914 L/h | Standard Deviation 6.7903 |
| Pralatrexate | Steady State Clearance [CLss] for R-pralatrexate | Pralatrexate-R Cycle 1 Week 6 (20 mg/m2) | 16.3789 L/h | Standard Deviation 5.3859 |
| Pralatrexate | Steady State Clearance [CLss] for R-pralatrexate | Pralatrexate-R Cycle 1 Week 6 (30 mg/m2) | 19.8406 L/h | Standard Deviation 8.9265 |
Secondary
Steady State Clearance [CLss] for S-pralatrexate
The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.
Time frame: Cycle 1 day 1, Cycle 1 week 6（Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection）
Population: PK population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Pralatrexate | Steady State Clearance [CLss] for S-pralatrexate | Pralatrexate-S Cycle 1 Day 1 (30 mg/m2) | 34.6341 L/h | Standard Deviation 17.9816 |
| Pralatrexate | Steady State Clearance [CLss] for S-pralatrexate | Pralatrexate-S Cycle 1 Week 6 (20 mg/m2) | 27.9794 L/h | Standard Deviation 8.4317 |
| Pralatrexate | Steady State Clearance [CLss] for S-pralatrexate | Pralatrexate-S Cycle 1 Week 6 (30 mg/m2) | 45.2022 L/h | Standard Deviation 22.4576 |
Secondary
Steady State Volume of Distribution [Vdss] for R-pralatrexate
The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.
Time frame: Cycle 1 day 1, Cycle 1 week6(Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection)
Population: PK population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Pralatrexate | Steady State Volume of Distribution [Vdss] for R-pralatrexate | Pralatrexate-R Cycle 1 day1（30mg/m2） | 194.1589 L | Standard Deviation 87.4028 |
| Pralatrexate | Steady State Volume of Distribution [Vdss] for R-pralatrexate | Pralatrexate-R Cycle 1 week6（20mg/m2） | 344.2511 L | Standard Deviation 109.8671 |
| Pralatrexate | Steady State Volume of Distribution [Vdss] for R-pralatrexate | Pralatrexate-R Cycle 1 week6（30mg/m2） | 329.1892 L | Standard Deviation 251.4938 |
Secondary
Steady State Volume of Distribution [Vdss] for S-pralatrexate
The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.
Time frame: Cycle 1 day 1, Cycle 1 week 6（Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection）
Population: PK population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Pralatrexate | Steady State Volume of Distribution [Vdss] for S-pralatrexate | Pralatrexate-S Cycle 1 Day 1 (30 mg/m2) | 517.1628 L | Standard Deviation 292.2888 |
| Pralatrexate | Steady State Volume of Distribution [Vdss] for S-pralatrexate | Pralatrexate-S Cycle 1 Week 6 (20 mg/m2) | 1110.6541 L | Standard Deviation 548.2687 |
| Pralatrexate | Steady State Volume of Distribution [Vdss] for S-pralatrexate | Pralatrexate-S Cycle 1 Week 6 (30 mg/m2) | 1680.6116 L | Standard Deviation 2292.0216 |
Secondary
Terminal Phase Half-life [t1/2Z] for R-pralatrexate
The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.
Time frame: Cycle 1 day 1, Cycle 1 week 6（Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection）
Population: PK population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Pralatrexate | Terminal Phase Half-life [t1/2Z] for R-pralatrexate | Pralatrexate-R Cycle 1 Day 1 (30 mg/m2) | 8.5040 h | Standard Deviation 3.4927 |
| Pralatrexate | Terminal Phase Half-life [t1/2Z] for R-pralatrexate | Pralatrexate-R Cycle 1 Week 6 (20 mg/m2) | 14.6089 h | Standard Deviation 0.197 |
| Pralatrexate | Terminal Phase Half-life [t1/2Z] for R-pralatrexate | Pralatrexate-R Cycle 1 Week 6 (30 mg/m2) | 11.8249 h | Standard Deviation 4.3282 |
Secondary
Terminal Phase Half-life [t1/2Z] for S-pralatrexate
The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.
Time frame: Cycle 1 day 1, Cycle 1 week 6（Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection）
Population: PK population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Pralatrexate | Terminal Phase Half-life [t1/2Z] for S-pralatrexate | Pralatrexate-S Cycle 1 Day 1 (30 mg/m2) | 10.8634 h | Standard Deviation 5.6517 |
| Pralatrexate | Terminal Phase Half-life [t1/2Z] for S-pralatrexate | Pralatrexate-S Cycle 1 Week 6 (20 mg/m2) | 26.2505 h | Standard Deviation 7.7381 |
| Pralatrexate | Terminal Phase Half-life [t1/2Z] for S-pralatrexate | Pralatrexate-S Cycle 1 Week 6 (30 mg/m2) | 24.8987 h | Standard Deviation 23.2607 |
Secondary
Time of Cmax Observation [Tmax] for R-pralatrexate
The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.
Time frame: Cycle 1 day 1, Cycle 1 week 6（Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection）
Population: PK population
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Pralatrexate | Time of Cmax Observation [Tmax] for R-pralatrexate | Pralatrexate-R in Cycle 1 day 1（30mg/m2） | 0.1000 h |
| Pralatrexate | Time of Cmax Observation [Tmax] for R-pralatrexate | Pralatrexate-R in Cycle 1 week 6（20mg/m2） | 0.1000 h |
| Pralatrexate | Time of Cmax Observation [Tmax] for R-pralatrexate | Pralatrexate-R in Cycle 1 week 6（30mg/m2） | 0.1000 h |
Secondary
Time of Cmax Observation [Tmax] for S-pralatrexate
The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.
Time frame: Cycle 1 day 1, Cycle 1 week 6（Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection）
Population: PK population
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Pralatrexate | Time of Cmax Observation [Tmax] for S-pralatrexate | Pralatrexate-S in Cycle 1 day 1（30mg/m2） | 0.1000 h |
| Pralatrexate | Time of Cmax Observation [Tmax] for S-pralatrexate | Pralatrexate-S in Cycle 1 week 6（20mg/m2） | 0.1000 h |
| Pralatrexate | Time of Cmax Observation [Tmax] for S-pralatrexate | Pralatrexate-S in Cycle 1 week 6（30mg/m2） | 0.1000 h |
Secondary
Time to Response (TTR)
Time to response was measured from first day of treatment to the first date of documented response.
Time frame: 2 years
Population: The secondary analyses was performed using the safety population and repeated using the per-protocol population.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Pralatrexate | Time to Response (TTR) | 2.0947 months | Standard Deviation 1.659 |